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Long-term Implications of Reocclusion on 
Left Ventricular Size and Function After 
Successful Thrombolysis for First 
Anterior Myocardial Infarction
Francisca Nijland, MD; Otto Kamp, MD, PhD; Freek W.A. Verheugt, MD, PhD;
Gerrit Veen, MD; Cees A. Visser, MD, PhD
Background  Successful thrombolysis can prevent left ven­
tricular dilatation after acute myocardial infarction. However, in 
almost 30% of patients, reocclusion occurs. The aim o f  this study 
was to assess the long-term implications o f  reocclusion on left 
ventricular size and function.
Methods and Results Fifty-six patients were studied with 
two-dimensional echocardiography at baseline (2 ± 1.6 days) and 
5.0± 1.4 years after first anterior myocardial infarction. All pa­
tients (a subset of those enrolled in the APRICOT trial) had a 
patent infarct-related artery when studied < 4 8  hours after throm­
bolysis and underwent repeat coronary angiography at 3 months. 
Baseline characteristics were comparable in patients with (n=  17) 
and without reocclusion (n=39). Left ventricular volume indexes 
were stable in patients without reocclusion. Patients with reoc­
clusion, however, showed a significant increase in end-diastolic 
volume index (EDVI; P = .0 0 8 ) and end-systolic volume index 
(ESVI; P=.039). Furthermore, patients without reocclusion dem-
L eft ventricular remodeling after acute myocardial 
infarction, resulting in enlargement of the ven­
tricle, is a progressive process beginning in the 
early phase and continuing for months and years.1-4 It 
occurs predominantly after a large transmural anterior 
wall infarction2*5 and carries an adverse prognosis.6*7 
There are supporting experimental and clinical data that 
successful reperfusion of the infarct-related artery can 
prevent this sequela by limiting infarct expansion.8-10 Re­
cent clinical studies have shown that infarct-related artery 
patency is one of the most important determinants for 
ventricular remodeling after myocardial infarction.4*1 U2 
Initial success of thrombolysis, however, is followed by 
reocclusion in almost 30% of patients within 3 months 
after myocardial infarction.13*14 Reocclusion is associated 
with a more complicated hospital course,15 impaired 
short-term recovery of regional and global ventricular 
function,15-16 and an increase in end-systolic volume 3
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onstrated improvement in wall motion score index (WMSI; 
P = .0 0 0 1 )  and ejection fraction (EF; P = .0 1 6 ) ,  whereas patients 
with reocclusion did not. After 5 years, patients with reocclusion 
had significantly larger volume indexes (EDVI, 99± 41  versus 
7 6 ± 2 2  m L/m 2, P = .007; ESVI, 5 9 + 4 0  versus 3 9 ± 2 0  mL/m2, 
i ^ .0 1 7 )  and more compromised left ventricular function 
(WMSI, 1.63'±0,33 versus 1 .39±0.32, ^ = .013 ; EF, 45±13% 
versus 51±11% , P - ,0 1 1 )  than patients without reocclusion. 
Multivariate analysis identified baseline WMSI and reocclusion 
as significant independent predictors o f left ventricular dilatation.
Conclusions  Reocclusion o f  the infarct-related artery within
3 months o f  successful thrombolysis is associated with left ven­
tricular dilatation and is detrimental to functional recovery o f  left 
ventricular function 5 years after first anterior myocardial infarc­
tion. (Circulation. 1997;95:111-117.)
Key W ords  • myocardial infarction • occlusion • 
thrombolysis • echocardiography • remodeling
months after myocardial infarction.16 Long-term data 
with respect to reocclusion are limited.17 Therefore, the 
aim of this study was to determine the implications of 
reocclusion on left ventricular size and function 5 years 
after first anterior myocardial infarction.
Methods
Patient Population
The study population consisted of 56 patients who had been 
enrolled in the Antithrombotics in the Prevention of Reocclusion  
in Coronary Thrombolysis (APRICOT) trial. s3 The entry criteria 
and study protocol have been described in detail previously. 13 In 
brief, patients younger than 71 years with symptoms o f  acute 
myocardial infarction o f  < 4  hours’ duration were included if  ST- 
segment elevation o f  > 0 .2  mV was present in two contiguous 
leads of a standard 12-lead ECG. All patients received intrave­
nous thrombolytic therapy with streptokinase or anistreplase. 
Coronary angiography was performed within 48 hours of throm­
bolytic treatment. Only patients with a patent infarct-related ar­
tery, as described below, were eligible to enter the study. Then, 
patients were randomized to receive either coumadin, aspirin, or 
placebo. After 3 months, repeat coronary angiography was per­
formed to assess reocclusion. A conservative strategy was in­
tended, implying that revascularization procedures were per­
formed only for reasons of recurrent angina refractory to medical 
therapy. In case o f  coronary angioplasty within 3 months, the 
status o f  the infarct-related artery before angioplasty was used 
for analysis.
For the present study, only patients with a left anterior descend­
ing artery-related myocardial infarction, enrolled in the Free Uni­
versity Hospital, who fulfilled the following criteria were se­
lected: ( 1) enzymatically proven myocardial infarction, defined
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as creatine kinase elevation exceeding twice the uppei limit ol 
normal; (2 ) both first and second coronary angiography were per­
formed; (3) two-dimensional echocardiography of adequate qual­
ity for quantitative analysis was performed during the early hos­
pital phase; (4) reocclusion had occurred in the absence oí 
documented reinfarction; and (5) no Q-wave myocardial rein- 
faretion had occurred during long-term follow-up. Q-wave myo­
cardial reinfarction was defined as recurrent ischemic chest pain 
accompanied by a rise in cardiac enzymes and appearance of new 
Q waves on the ECG. Surviving patients were invited to partic­
ipate in the follow-up investigation, which consisted of a two- 
dimensional echocardiographic study. Of three patients who died 
during follow-up, an echocardiogram taken < 3  months before 
death was available for analysis. On the basis of the results of the 
second coronary angiography, two groups of patients were de­
fined: patients with and without reocclusion.
Coronary Angiography
Ail coronary angiograms of the APRICOT trial have been ex­
amined by an angiography committee, which consisted of three 
experienced cardiologists blinded to treatment allocation and 
clinical course of the patients. Decisions were made by consen­
sus. Patency of the infarct-related artery was classified according 
to the European Cooperative Study Group18 as grade 0, normal 
coronary artery; grade 1, <50% diameter stenosis; grade 2, 50% 
to 90% diameter stenosis; grade 3,91% to 99% diameter stenosis, 
complete filling within three cycles; grade 4, 91% to 99% di­
ameter stenosis, no complete filling within three cycles; and grade
5, 100% diameter stenosis. Patients with grade 1 to 3 stenosis 
were eligible for the study. Reocclusion was defined as grade 4 
or 5 stenosis at follow-up coronary angiography. Quantitative 
angiographic analysis of the residual stenosis was performed with 
a personal computer-based QCA system (QCA-CMS, MEDIS 
Medical Imaging Systems). End-diastolic cine frames of at least 
two orthogonal views, clearly demonstrating the stenotic coro­
nary segment, were selected, magnified, and digitized. The 
boundaries of the selected segment of the coronary artery were 
detected automatically. 19 A diameter was computed perpendicu­
lar to the vessel centerline as the distance between the edges. A 
computer estimation of the original arterial dimension at the site 
of obstruction was used to calculate the interpolated reference 
diameter. The mean percentage diameter stenosis was used for 
subsequent analysis.
Two-dimensional Echocardiography
The early echocardiographic studies were performed with ei­
ther an Advanced Technologies Laboratory ADR-4000 or a Hew­
lett-Packard Sonos 1000 using a 3.0- or 3.5-MHz transducer; fol­
low-up echocardiograms were performed by means of a 
Hewlett-Packard Sonos 1500 using a 2.5-MHz transducer. All 
examinations included standard parasternal and apical views and 
were stored on half-inch VHS videotape for subsequent analysis. 
Regional wall motion was assessed semi quantitatively by two 
experienced observers unaware of clinical or angiographic data, 
using a 13-segment division of the left ventricle.2D Wall motion 
for each segment was graded visually as 1, normokinesia; 2 , hy­
pokinesia; 3, akinesia; and 4, dyskinesia. Wall motion score index 
was calculated by summing the scores for each segment and di­
viding by the number of segments analyzed. Left ventricular end- 
diastolic and end-systolic volumes were determined from apical 
two- and four-chamber views by use of the Simpson biplane for­
mula according to the recommendations of the American Society 
of Echocardiography.21 Tracing of the endocardial borders was 
performed on a digitized frame from the technically best cardiac 
cycle (Image Vue, Nova Microsonics), and volumes were nor­
malized for body surface area. An increase of >20% in end- 
diastolic volume index (EDVI) from baseline to follow-up was 
defined as left ventricular dilatation.22'24 Ejection fraction was 
calculated as (End-Diastolic Volume-End-Systolic Volume)/ 
End-Diastolic Volume.
Statistical Analysis
Data are presented as m ean±SD. Comparisons between groups 
for continuous data were made with an unpaired Student’s t test. 
Differences between proportions were assessed by x 2 analysis. 
Fisher’s exact test was used if there was an expected cell value 
<5. Changes in left ventricular volume and function over time 
were analyzed by paired Student’s t test. Statistical significance 
was defined as a value of P c .0 5 .  Stepwise logistic regression 
analysis was performed to determine which variables were in­
dependent predictors of left ventricular dilatation,
Results
Study Group
Of 200 patients enrolled in the APRICOT trial in the 
Free University Hospital, 94 had a left anterior descending 
artery-related myocardial infarction. Eleven patients of 
this group underwent no second coronary angiography be­
cause of death (n=2), coronary surgery within 3 months 
(n= l), or patient refusal (n=8). Of the remaining 83 pa­
tients, 20 were excluded for aborted infarction (n=5), doc­
umented reinfarction during hospitalization (n=4), death 
without a second echocardiogram (n=8), or Q-wave myo­
cardial reinfarction during follow-up (n=3). Furthermore, 
in 3 patients, the first echocardiogram was of inadequate 
quality, and 4 patients were lost to follow-up.
Patient Characteristics
All 56 selected patients had a first myocardial infarction. 
Baseline characteristics of patients with and without reoc­
clusion are shown in Table 1. There were no significant 
differences between both groups with respect to age, sex, 
and medication or ventricular volume indexes and ejection 
fractions. Enzymatic infarct size and wall motion score 
index, both indicators of the extent of left ventricular dys­
function, were higher in patients who suffered reocclusion, 
although the difference was not significant. Patients with 
reocclusion had a higher mean percentage diameter ste­
nosis at first coronary angiography than patients with sus­
tained patency (P=.QQ01). Eleven patients suffered from 
recurrent angina pectoris before the second coronary an­
giography; 3 of these had reocclusion and 8 had no reoc­
clusion (P=NS). The incidence of non-Q-wave myocar­
dial reinfarction and unstable angina during the mean 
follow-up period of 5.0±1.4 years was similar (5% and 
18%, respectively, in patients with persistent patency ver­
sus 6% and 18% in patients with reocclusion). Hospital­
ization for heart failure had occurred in 3 patients with 
reocclusion (18%) compared with 1 patient without reoc­
clusion (2.6% ;P—NS). At the time of follow-up echocar­
diography, there were no differences in New York Heart 
Association class; all patients were in class I or II. Revas­
cularization procedures have been performed in 9 (23%) 
of the 39 patients without reocclusion compared with 4 
(24%) of the 17 patients with reocclusion (P=NS).
Left Ventricular Volumes
. (
Fig 1 shows the impact of reocclusion of the infarct- 
related artery on left ventricular volume. In patients with­
out reocclusion, left ventricular volume indexes were sta­
ble throughout the study period. EDVI tended to increase 
from 70±12 mL/m2 to 76±22 mL/m2, but this change was 
not statistically significant (P=.054). Also, end-systolic 
volume index (ESVI) remained unchanged, with a baseline 
value of 37± 11 mL/m2 and a follow-up value of 39±20
m L /m 2 ( jP = .5 8 \  In contrast, le ft  ventricular vo lu m e in ­
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T a b l e  1. Baseline Characteristics
Variables
No Reocclusion 
(n=39)
Reocclusion
(n=17) P
Age, y 56±10 53+10 NS
Male, n (%) 30 (77) 17 (100) NS
Hypertension, n (%) 11 (28) 4 (24) NS
Time to thrombolysis, h 1.8±0.8 2.3+0.9 NS
Peak creatine kinase, U/L 2000+1901 2391+1281 NS
Peak MB fraction, U/L 163±126 184+123 NS
Time to peak, h 12±4 13±4 NS
No. leads with ST elevation* 5.51 ±1.35 5.12±1.65 NS
No. pathological Q wavesf 2.1±1.5 2.4+1.8 NS
Multivessel disease, n {%) 14 (36) 8(47) NS
% Diameter stenosis IRV$ 51±12 64+5 .0001
Medication at hospital discharge 1
Nitrates, n (%) 3(8) 1 (6) NS
0-Blockers, n (%) 28 (72) 11 (65) NS
Calcium antagonists, n {%) 2(5) 1 (6) NS
ACE inhibitors, n {%) 5(13) 2 (12) NS
End-diastolic volume index, mL/m2 70±12 76+14 NS
End-systolic volume index, mL/m2 37±11 42±11 NS
Ejection fraction, % 48 ±8 45+6 NS
Wall motion score index 1.55+0.24 1.64+0.21 NS
IRV indicates Infarct-related vessel. Values are mean 
*On the ECG before thrombolytic therapy. 
tOn the ECG at hospital discharge.
¿At first coronary angiography.
SD.
dexes increased significantly in patients with reocclusion, 
EDVI from 76±14 mL/m2 to 99±4I mL/m2 (P=.008) and 
ESVI from 42± 11 mL/m2 to 59±40 mL/m2 (P=.039). The 
mean percentage change in volume indexes was signifi­
cantly higher in the reocclusion group than in patients with­
out reocclusion (EDVI, 23% versus 5%, P=.006; ESVI, 
17% versus 1.4%, P=.015). After 5 years, patients with 
reocclusion had significantly larger ED Vis and ESVIs than 
patients with sustained patency (EDVI, P—.007; ESVI, 
P=. 017).
Left Ventricular Function
Fig 2 displays the impact of reocclusion on left ventric­
ular function. In patients without reocclusion, ejection 
fraction increased significantly from 48±8% to 51 ±11% 
(P=.016). With reocclusion, there was no change.: the 
baseline value was 45 ±6%, and the follow-up value was 
45±13% (P=NS). At long-term follow-up, patients with­
out reocclusion had a higher ejection fraction than patients 
with reocclusion (P=.077).
Patients without reocclusion showed an improvement in 
regional wall motion: the wall motion score index decreased
significantly from 1.55±0.24 to 1.39±0.32 (Pc.0001). In 
contrast, patients with reocclusion showed no change, with 
a baseline value of 1.64±0.2'1 and a follow-up value of 
1.63±0.33 (P=NS). After 5 years, patients with sustained 
patency had a significantly better regional left ventricular 
function than patients with reocclusion (P=.013).
Predictors of Left Ventricular Dilatation
Left ventricular dilatation, defined as an increase of 
>20% in EDVI, was evident in 12 (21%) of the 56 pa­
tients. Table 2 shows the univariate predictors of left ven­
tricular dilatation. Peak MB fraction, number of leads with 
&l-mm ST elevation, number of pathological Q waves, 
wall motion score index, ESVI, and ejection fraction at 
baseline as well as reocclusion were all associated with a 
greater risk of left ventricular dilatation by univariate anal­
ysis. Logistic regression analysis revealed that baseline 
wall motion score index was more significantly related to 
ventricular dilatation than reocclusion and the number of 
Q waves on the ECG. When baseline wall motion score 
index was used as the first predictor in the multivariate 
model, reocclusion still added significantly to the predic-
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Fig 1. Change in left ventricular end-diastolic and end-systolic 
volume indexes between baseline and 5 years after myocardial 
infarction in patients with and without reocclusion.
Baseline Y ///A  Follow-up
Fig 2. Change in ejection fraction and wail motion score indexes 
between baseline and 5 years after myocardial infarction in pa­
tients with and without reocclusion.
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tion of dilatation. Fig 3 shows the relation between base­
line wall motion score index and the risk of left ventricular 
dilatation in patients with and without reocclusion. For a 
similar extent of regional dysfunction, the risk of ventric­
ular dilatation was smaller in patients without reocclusion 
than in patients with reocclusion. Patients with a high wall 
motion score index at baseline with reocclusion were at 
the highest risk for left ventricular dilatation.
Discussion
Left Ventricular Dilatation and Patency of the 
Infarct-Related Artery
The patency status of the infarct-related artery has been 
identified as one of the most important determinants for 
left ventricular dilatation after myocardial infarction.4'11*12 
Previous clinical studies25’28 have shown the detrimental“ 
effect of an occluded infarct-related artery on left ventric­
ular shape and volume. Forman et al25 studied 79 patients 
with a first anterior myocardial infarction without throm­
bolysis using cardiac catheterization within 6 months. Left 
ventricular aneurysm had developed in 25 (48%) of 52 
patients with an occluded left anterior descending artery 
in contrast to only 4 (15%) of 27 patients with a patent 
artery.25 Jeremy et al26 demonstrated that at each level of 
infarct size, patients with an occluded infarct-related artery 
at hospital discharge had a greater increase in left ventric­
ular volume at 1 month than patients with spontaneous 
reperfusion of this artery. The beneficial effect of throm­
bolytic therapy on left ventricular dilatation was shown in 
the GISSI trial,29 in which end-systolic volume was 
smaller in patients treated with thrombolysis than in pa­
tients assigned to standard care. However, the relation be­
tween infarct-related artery patency and ventricular dila­
tation in that study remained unclear because angiography 
was not performed. Recent experimental and clinical data 
indicate that successful reperfusion of the infarct-related 
artery, even beyond the time frame for myocardial salvage, 
can prevent or limit ventricular dilatation. 9-10‘12-30-35 The 
preventive effect of late reperfusion seems to be indepen­
dent of the limitation of infarct size.8-12 Specifically, it has
%
Fig 3. Relation between baseline wall motion score index ar 
the risk of left ventricular dilatation in patients with and witho 
reocclusion. For a similar extent of regional dysfunction, the rii 
of ventricular dilatation is less in patients without reocclusion th* 
in patients with reocclusion. Patients with a high wail motk 
score index at baseline with reocclusion are at highest risk i  
left ventricular dilatation.
been shown that late reperfusion acts by limitation of ii 
farct expansion.8-36’38
Data with respect to the impact of reocclusion aftc 
successful reperfusion on left ventricular dilatation ai 
scarce.16 Meijer et a l16 showed a trend toward dilatatio 
in patients with reocclusion 3 months after myocardh 
infarction. To our knowledge, no study has evaluate 
the long-term implications of reocclusion in this respec 
Therefore, the current study not only supports the pre 
vious findings but extends them in a significant way. Oi 
data demonstrate the importance of sustained patency c 
the infarct-related artery. This allowed preservation c 
EDVI and ESVI, whereas reocclusion results in an ap 
parent increase in these parameters. The favorable effec 
of successful reperfusion on ventricular dilatation ap 
pears to be attenuated by reocclusion. This observatio 
may be of prognostic importance because mortality in 
creases progressively with increased left ventricula 
volumes.7
Infarct-related artery patency as such is not the onl 
characteristic that is important with respect to ventricula
T a b le  2. Univariate Predictors of Left Ventricular Dilatation
No Dilatation Dilatation
Variables (n~44) (n=12) P
Age, y 55±10 53±11 NS
Male, n (%) 36 (82) 11 (92) NS
Peak creatine kinase, U/L 2001 ±1817 2371 ±1390 NS
Peak MB fraction, U/L 147±107 228 ±149 <.05
No. leads with ST elevation* 5.19±1.37 6.17±1.59 <.05
No. pathological Q wavesf 1.8±1.3 3.3±2.0 <,005
Muitivessel disease, n (%) 15 (34) 7(58) NS
% Diameter stenosis IRVij: 54±13 60±9 NS
Reocclusion,§ n (%) 9 (20) 8(67) <.005
Medication at hospital discharge
ACE inhibitors, n (%) 4(9) 3 (25) NS
End-diastolic volume index, mL/m2 II 71 ±12 78±17 NS
End-systolic volume index, mL/m2 II 37 ±11 45±13 <.05
Ejection fraction, % II 48±8 43±5 <.05
Wall motion score index II 1.53±0.23 1.76±0.17 <.005
IRV indicates infarct-related vessel. Values are mean±SD. 
*On the ECG before thrombolytic therapy. 
tOn the ECG at hospital discharge. 
iA t first coronary angiography.
§At second coronary angiography.
II At baseline.
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dilatation; Leung and Lau39 demonstrated that patients 
with a minimal lumen diameter <1.5 mm show a signif­
icantly greater increase in left ventricular volume than 
patients with a minimal lumen diameter >1.5 mm. How­
ever, their results may be attributable to the expected 
higher rate of reocclusion in patients with a minimal lu­
men diameter <1.5 mm. Reocclusion of the infarct-re­
lated artery within the first year after thrombolysis might 
be as high as 25% to 30%13-14-40 and is related to the se­
verity of the residual stenosis.40-41 In the present study, 
the percentage diameter stenosis after thrombolysis was 
not related to left ventricular dilatation by either univar­
iate or multivariate analysis, whereas reocclusion was a 
significant independent predictor. Also, in patients with­
out reocclusion, there was no relation between the mean 
percentage diameter stenosis at first coronary angiogra­
phy and changes in EDVI from baseline to follow-up 
(r=.18, P=.21). Future clinical studies are needed to con­
firm the hypothesis that the occurrence of re occlusion, 
not the severity of residual stenosis, is related to ventric­
ular dilatation.
Determinants of Left Ventricular Dilatation
Previous clinical studies have evaluated variables that 
predict an increase in left ventricular volume after myo­
cardial infarction.4*11 *42’43 In addition to the patency 
status of the infarct-related artery,4-11 the extent of left 
ventricular dysfunction (as assessed by enzymatic in­
farct size,43 echocardiography,42 ventriculography,11 or 
radionuclide imaging4*44) and infarct location (anterior4) 
are independently associated with progressive left ven­
tricular dilatation. Other contributing factors are left 
ventricular end-diastolic pressure,11 baseline left ven­
tricular volume,42-43 and transmurality.45 Our data are 
consistent with these previous findings. Interestingly, 
the number of pathological Q waves on the ECG at hos­
pital discharge is a strong univariate predictor of ven­
tricular dilatation. Despite the fact that a Q wave is nei­
ther sensitive nor specific for transmurality,46 a high 
number of Q waves probably reflects greater transmural­
ity and greater infarct size. Jugdutt et al47 showed in an 
experimental study that anterior Q-wave infarction is 
associated with greater transmurality and more remod­
eling than non-Q-wave infarction. Multivariate analysis 
of the present data demonstrates that baseline wall mo­
tion score index and reocclusion have an additive and 
independent effect on ventricular remodeling. This sug­
gests that efforts to limit infarct size by achieving re­
perfusion as early as possible after coronary occlusion 
must be followed by efforts to maintain patency.
Left Ventricular Function
It has been demonstrated that successful early throm­
bolysis results in improvement of regional and global sys­
tolic function by salvage of jeopardized myocardium.48-49 
However, the recovery of this salvaged myocardium is sig­
nificantly impaired by reocclusion.15*16-50 Two previous 
clinical studies,15-16 both performed shortly after myocar­
dial infarction, reported that left ventricular function was 
significantly better in patients without reocclusion than in 
those with reocclusion. This difference was largely due to 
recovery of infarct-zone function in patients without reoc­
clusion. The present study shows similar results after a 
time span of 5 years. Patients with sustained patency show 
improvement in wall motion score index and ejection frac­
tion, whereas patients with reocclusion do not. Thus, the 
beneficial salvaging effects of reperfusion over time are 
attenuated by reocclusion.
Study Limitations
In interpreting our findings, several limitations must be 
considered. First, the present data were obtained in a se­
lected group of patients, and a certain selection bias cannot 
be excluded. The requirement for invasive restudy at 3 
months and repeat echocardiography at 5 years eliminated 
some of the highest-risk patients for left ventricular re­
modeling. Furthermore, the results cannot be applied uni­
versally to patients with inferior myocardial infarction. 
The decision to study only patients with anterior wall in­
farction was based on the observation that patients at risk 
for remodeling are predominantly those with a large an­
terior myocardial infarction.5 Another limitation of our 
study is the small number of patients. It may be too small 
to detect baseline clinical differences between patients 
with and without reocclusion, owing to insufficient power. 
This may be especially important for differences in infarct 
size, which could influence long-term left ventricular di­
latation. Finally, the role of intervening revascularization 
procedures after the second coronary angiography remains 
unclear from this study. In one of the four patients who 
underwent a revascularization procedure in the reocclusion 
group, it was performed shortly after the second coronary 
angiography. This patient showed an improvement in re­
gional and global left ventricular function, as well as a 
decrease in volume indexes. The other three patients (in 
whom the procedure was performed after a mean of 41 
months) all demonstrated a deterioration in ventricular 
function and an increase in volume indexes.
Clinical Implications
Our findings support the “open artery hypothesis” 51*52 
and emphasize the importance of sustained patency of the 
infarct-related artery. Because left ventricular function and 
volume are both important prognostic indicators, the dif­
ferences that we observed between the groups with and 
without reocclusion are likely to be of prognostic signifi­
cance. Our observations underline the importance of pre­
vention and detection of reocclusion. Future clinical stud­
ies should address the value of angioplasty or coronary 
artery bypass surgery in prevention and treatment of re­
occlusion and determine the optimal timing of these 
procedures.
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